MMV welcomes proposals in the following four areas:
1. Compounds addressing the key priorities of the malaria eradication agenda
New families of molecules in the hit-to-lead and lead optimization stages are sought that either:
- kill or reactivate hypnozoites for use as part of a P. vivax radical cure;
- have dual activity against asexual and sexual stages (gametocytes) for treatment and transmission blocking;
- are novel and without G6PD deficiency liabilities.
2. Assays addressing liver stage vivax
- Novel, robust and validated in vitro or in vivo models of vivax liver stages are sought that are suitable for immediate compound testing. Please see the criteria for P. vivax for specific details.
3. Asexual liver and blood stages
Novel chemical series with EC50<1μM and which have one or more of the following key features:
- A novel mechanism of action;
- A long half-life (ideally >4h in rodents) and confirmed in vivo efficacy;
- No evidence of genotoxic or developmental issues along with a plan to continuously examine these aspects during the Discovery phase and also once a preclinical candidate is selected.
- For advanced series, we are seeking compounds with, ideally, a predicted human half-life >100h and a predicted single human dose <1g.
Please see the published MMV Target Candidate Profiles for more information. Early target validation falls outside of our mandate.
4. Resistant strains
To help select future antimalarial candidate drugs, we would like to hear from groups who have stable parasite cultures that show significant resistance to any of the drugs listed below:
- Piperaquine, Pyronaridine, Mefloquine, Amodiaquine, Lumefantrine
If resistance is confirmed then MMV would welcome the opportunity to add a resistant clone to our screening panel.
Templates for the 3-page Letter of Interest and 1-2 page Submission of resistant strains can be found in the right-hand column of this page.
All applications using the specified templates should be sent to proposals [at] mmv.org by 12 noon CET Tuesday, 31 March 2015.